Drug Pricing
Drug Pricing
Advancing Innovation and Access
We analyze the value that therapies bring to patients and develop novel payment models for rewarding innovation while restraining costs.
Featured Perspective
Medicare Beneficiaries Face Much Higher Drug Costs as Plans Quickly Shift to Coinsurance
The share of stand-alone prescription drug plans using coinsurance for preferred brand name drugs surged in recent years, exposing more patients to list prices that are often artificially inflated.
Experts: Erin Trish
Related Subtopics
The Schaeffer Center is a nationally recognized leader on drug pricing research, with a particular focus on the economic system that distributes and pays for drugs. Our experts develop effective strategies for containing costs while rewarding new treatments based on the value they provide to patients.
Top Drug Pricing Stories View All
News
Analysis Finds Meaningful Impact on Pharmaceutical Innovation From Reduced Revenues
Featured Experts: Darius Lakdawalla, Dana Goldman, Karen Van Nuys
In The News View All
Medscape
Medicare coverage of obesity drugs could presure other insurers to follow suit, Ward says
Featured Experts: Alison Sexton Ward
Yahoo Finance
Joyce addresses possible impacts of pharmaceutical tariffs
Featured Experts: Geoffrey Joyce
Oprah Daily
Qato discusses disparities in GLP-1 coverage
Featured Experts: Dima M. Qato
STAT
Medicare Drug Price Negotiations Need Something New: A Floor
Featured Experts: Darius Lakdawalla
STAT
Medicare Should Cover Wegovy — but Not Negotiate Its Price
Featured Experts: Joseph Grogan
Featured White Paper
Mitigating the IRA’s Adverse Impacts on the Prescription Drug Market
Although the Inflation Reduction Act of 2022 (IRA) aimed to increase patient access to prescription drugs and decrease spending, researchers warn that it may have unintended negative impacts on patients in the long run. A Schaeffer Center white paper recommends three strategies to mitigate adverse impacts of the IRA.
Read the White PaperTeam View All Drug Pricing Experts
